Prostate Cancer Research - Symptoms, Genetics, Screening, Treatment, Information

Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.


Prostate Cancer Research Today

Home

View Latest Issue

Information About Prostate Cancer

Books on Prostate Cancer

Advertising in Research Today

View Other Research Today Publications



Volume 2 (2005), Issue 3 (March)

  1. Discordance analysis characteristics as a new method to compare the diagnostic accuracy of tests: example of complexed versus total prostate-specific antigen.
    Clin Chem, 51(3): 532-9. [Abstract] [Full-text]
  2. Neoxanthin and fucoxanthin induce apoptosis in PC-3 human prostate cancer cells.
    Cancer Lett, 220(1): 75-84. [Abstract] [Full-text]
  3. Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells.
    Eur J Cancer, 41(4): 624-34. [Abstract] [Full-text]
  4. Shifting paradigms in prostate cancer; docetaxel plus low-dose prednisone - finally an effective chemotherapy.
    Eur J Cancer, 41(4): 502-7. [Abstract] [Full-text]
  5. Genetic susceptibility to prostate, breast, and colorectal cancer among Nordic twins.
    Biometrics, 61(1): 55-63. [Abstract] [Full-text]
  6. Optical properties of human prostate at 732 nm measured in mediated photodynamic therapy.
    Photochem Photobiol, 81(1): 96-105. [Abstract] [Full-text]
  7. Serum alpha-tocopherol and gamma-tocopherol in relation to prostate cancer risk in a prospective study.
    J Natl Cancer Inst, 97(5): 396-9. [Abstract] [Full-text]
  8. Association of a genetic polymorphism of the E-cadherin gene with prostate cancer in a Japanese population.
    Jpn J Clin Oncol, 35(3): 158-61. [Abstract] [Full-text]
  9. Novel electrical detection of label-free disease marker proteins using piezoresistive self-sensing micro-cantilevers.
    Biosens Bioelectron, 20(10): 1932-8. [Abstract] [Full-text]
  10. Complications of transrectal versus transperineal prostate biopsy.
    ANZ J Surg, 75(1): 48-50. [Abstract] [Full-text]
  11. Antagonist of growth hormone-releasing hormone induces apoptosis in LNCaP human prostate cancer cells through a Ca2+-dependent pathway.
    Proc Natl Acad Sci U S A, 102(9): 3435-40. [Abstract] [Full-text]
  12. Pomegranate (Punica granatum) pure chemicals show possible synergistic inhibition of human PC-3 prostate cancer cell invasion across Matrigel.
    Invest New Drugs, 23(2): 121-2. [Abstract] [Full-text]
  13. BAF57 governs androgen receptor action and androgen-dependent proliferation through SWI/SNF.
    Mol Cell Biol, 25(6): 2200-15. [Abstract] [Full-text]
  14. Altered expression of alpha-methylacyl-coenzyme A racemase in prostatic adenocarcinoma following hormone therapy.
    Am J Clin Pathol, 123(4): 553-61. [Abstract] [Full-text]
  15. Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy.
    J Pharm Sci, 94(4): 788-97. [Abstract] [Full-text]
  16. Beliefs about illness and quality of life among men with erectile dysfunction.
    Int J Impot Res, 17(2): 142-7. [Abstract] [Full-text]
  17. Prospective study of quantitation of plasma DNA levels in the diagnosis of malignant versus benign prostate disease.
    Clin Cancer Res, 11(4): 1394-9. [Abstract] [Full-text]
  18. Social disparities and prostate cancer: mapping the gaps in our knowledge.
    Cancer Causes Control, 16(1): 45-53. [Abstract] [Full-text]
  19. Pilot study: potential role of vitamin D (Cholecalciferol) in patients with PSA relapse after definitive therapy.
    Nutr Cancer, 51(1): 32-6. [Abstract] [Full-text]
  20. Rectal wall sparing by dosimetric effect of rectal balloon used during intensity-modulated radiation therapy (IMRT) for prostate cancer.
    Med Dosim, 30(1): 25-30. [Abstract] [Full-text]
  21. Impact of setup uncertainty in the dosimetry of prostate and surrounding tissues in prostate cancer patients treated with Peacock/IMRT.
    Med Dosim, 30(1): 1-7. [Abstract] [Full-text]
  22. Constructions of masculinity following prostatectomy-induced impotence.
    Soc Sci Med, 60(10): 2249-59. [Abstract] [Full-text]
  23. Ultraviolet radiation: effects on risks of prostate cancer and other internal cancers.
    Mutat Res, 571(1): 207-19. [Abstract] [Full-text]
  24. Osteoporosis risk and interest in strength training in men receiving androgen ablation therapy for locally advanced prostate cancer.
    J Am Acad Nurse Pract, 17(3): 113-22. [Abstract] [Full-text]
  25. Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer.
    Cancer Res, 65(5): 1941-51. [Abstract] [Full-text]
  26. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
    Cancer Res, 65(5): 1849-57. [Abstract] [Full-text]
  27. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.
    Cancer Res, 65(5): 1761-9. [Abstract] [Full-text]
  28. Osteoprotegerin in prostate cancer bone metastasis.
    Cancer Res, 65(5): 1710-8. [Abstract] [Full-text]
  29. Cannabinoid receptor as a novel target for the treatment of prostate cancer.
    Cancer Res, 65(5): 1635-41. [Abstract] [Full-text]
  30. Gamma-tocopherol induces apoptosis in androgen-responsive LNCaP prostate cancer cells via caspase-dependent and independent mechanisms.
    Ann N Y Acad Sci, 1031: 399-400. [Abstract] [Full-text]
  31. Gamma-tocotrienol metabolism and antiproliferative effect in prostate cancer cells.
    Ann N Y Acad Sci, 1031: 391-4. [Abstract] [Full-text]
  32. Inverse treatment planning based on MRI for HDR prostate brachytherapy.
    Int J Radiat Oncol Biol Phys, 61(4): 1267-75. [Abstract] [Full-text]
  33. Use of deformed intensity distributions for on-line modification of image-guided IMRT to account for interfractional anatomic changes.
    Int J Radiat Oncol Biol Phys, 61(4): 1258-66. [Abstract] [Full-text]
  34. Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer.
    Int J Radiat Oncol Biol Phys, 61(4): 1251-7. [Abstract] [Full-text]
  35. Combining vascular and cellular targeting regimens enhances the efficacy of photodynamic therapy.
    Int J Radiat Oncol Biol Phys, 61(4): 1216-26. [Abstract] [Full-text]
  36. Toward a definition of a threshold for harmless doses to the anal-sphincter region and the rectum.
    Int J Radiat Oncol Biol Phys, 61(4): 1035-44. [Abstract] [Full-text]
  37. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
    Int J Radiat Oncol Biol Phys, 61(4): 1019-34. [Abstract] [Full-text]
  38. Gastrointestinal toxicity and its relation to dose distributions in the anorectal region of prostate cancer patients treated with radiotherapy.
    Int J Radiat Oncol Biol Phys, 61(4): 1011-8. [Abstract] [Full-text]
  39. What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
    Int J Radiat Oncol Biol Phys, 61(4): 1003-10. [Abstract] [Full-text]
  40. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy.
    Int J Radiat Oncol Biol Phys, 61(4): 993-1002. [Abstract] [Full-text]
  41. Prostate motion and isocenter adjustment from ultrasound-based localization during delivery of radiation therapy.
    Int J Radiat Oncol Biol Phys, 61(4): 984-92. [Abstract] [Full-text]
  42. Application of the No Action Level (NAL) protocol to correct for prostate motion based on electronic portal imaging of implanted markers.
    Int J Radiat Oncol Biol Phys, 61(4): 969-83. [Abstract] [Full-text]
  43. Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression.
    Cancer, 103(6): 1186-94. [Abstract] [Full-text]
  44. Fulminant hepatic failure secondary to metastatic prostate cancer.
    Urol Int, 74(2): 185-7. [Abstract] [Full-text]
  45. Antisense inhibition of methylenetetrahydrofolate reductase reduces cancer cell survival in vitro and tumor growth in vivo.
    Clin Cancer Res, 11(5): 2047-52. [Abstract] [Full-text]
  46. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism.
    Clin Cancer Res, 11(5): 1999-2007. [Abstract] [Full-text]
  47. Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer.
    Clin Cancer Res, 11(5): 1854-62. [Abstract] [Full-text]
  48. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480.
    Clin Cancer Res, 11(5): 1815-20. [Abstract] [Full-text]
  49. Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth.
    Clin Cancer Res, 11(5): 1704-12. [Abstract] [Full-text]
  50. A nonclassic CCAAT enhancer element binding protein binding site contributes to alpha-methylacyl-CoA racemase expression in prostate cancer.
    Mol Cancer Res, 3(2): 110-8. [Abstract] [Full-text]
  51. Apigenin drives the production of reactive oxygen species and initiates a mitochondrial mediated cell death pathway in prostate epithelial cells.
    Prostate, 63(2): 131-42. [Abstract] [Full-text]
  52. C/EBPdelta is a downstream mediator of IL-6 induced growth inhibition of prostate cancer cells.
    Prostate, 63(2): 143-54. [Abstract] [Full-text]
  53. Induction of AP-1 activity by androgen activation of the androgen receptor in LNCaP human prostate carcinoma cells.
    Prostate, 63(2): 155-68. [Abstract] [Full-text]
  54. Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines.
    Prostate, 63(2): 187-97. [Abstract] [Full-text]
  55. Regulation of expression of the early growth response gene-1 (EGR-1) in malignant and benign cells of the prostate.
    Prostate, 63(2): 198-207. [Abstract] [Full-text]
  56. Expression and functional study of estrogen receptor-related receptors in human prostatic cells and tissues.
    J Clin Endocrinol Metab, 90(3): 1830-44. [Abstract] [Full-text]
  57. Curative antitumor immune response is optimal with tumor irradiation followed by genetic induction of major histocompatibility complex class I and class II molecules and suppression of Ii protein.
    Hum Gene Ther, 16(2): 187-99. [Abstract] [Full-text]
  58. Virtually he@lthy: the impact of internet use on disease experience and the doctor-patient relationship.
    Qual Health Res, 15(3): 325-45. [Abstract] [Full-text]
  59. Positron emission tomography and bone metastases.
    Semin Nucl Med, 35(2): 135-42. [Abstract] [Full-text]
  60. Prostate cancer after exogenous testosterone replacement therapy in a patient with pituitary insufficiency.
    Scand J Urol Nephrol, 39(1): 87-8. [Abstract] [Full-text]
  61. Quality of life in patients with skeletal metastases of prostate cancer and status prior to start of endocrine therapy: results from the Scandinavian Prostate Cancer Group Study 5.
    Scand J Urol Nephrol, 39(1): 42-8. [Abstract] [Full-text]
  62. Pre- and post-treatment daily life function in patients with hormone resistant prostate carcinoma treated with radiotherapy for spinal cord compression.
    Radiother Oncol, 74(3): 259-65. [Abstract] [Full-text]
  63. Glucose deprivation increases mRNA stability of vascular endothelial growth factor through activation of AMP-activated protein kinase in DU145 prostate carcinoma.
    J Biol Chem, 280(11): 9963-72. [Abstract] [Full-text]
  64. Ku is a novel transcriptional recycling coactivator of the androgen receptor in prostate cancer cells.
    J Biol Chem, 280(11): 10827-33. [Abstract] [Full-text]
  65. Gene expression profiling revealed novel molecular targets of docetaxel and estramustine combination treatment in prostate cancer cells.
    Mol Cancer Ther, 4(3): 389-98. [Abstract] [Full-text]
  66. Chromosomal instability in peripheral blood lymphocytes and risk of prostate cancer.
    Cancer Epidemiol Biomarkers Prev, 14(3): 748-52. [Abstract] [Full-text]
  67. Centralized blood processing for the selenium and vitamin E cancer prevention trial: effects of delayed processing on carotenoids, tocopherols, insulin-like growth factor-I, insulin-like growth factor binding protein 3, steroid hormones, and lymphocyte viability.
    Cancer Epidemiol Biomarkers Prev, 14(3): 727-30. [Abstract] [Full-text]
  68. Resveratrol-induced gene expression profiles in human prostate cancer cells.
    Cancer Epidemiol Biomarkers Prev, 14(3): 596-604. [Abstract] [Full-text]
  69. Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States.
    Cancer Epidemiol Biomarkers Prev, 14(3): 590-5. [Abstract] [Full-text]
  70. Risk of prostate cancer in a randomized clinical trial of calcium supplementation.
    Cancer Epidemiol Biomarkers Prev, 14(3): 586-9. [Abstract] [Full-text]
  71. Biopsy of the prostate guided by transrectal ultrasound: relation between warfarin use and incidence of bleeding complications.
    Clin Radiol, 60(4): 459-63; discussion 457-8. [Abstract] [Full-text]
  72. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.
    Cancer Cell, 7(3): 239-49. [Abstract] [Full-text]
  73. Nucleotide-excision repair and prostate cancer risk.
    Cancer Lett, 220(2): 125-35. [Abstract] [Full-text]
  74. Signal transduction in prostate cancer progression.
    Clin Sci (Lond), 108(4): 293-308. [Abstract] [Full-text]
  75. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer.
    World J Urol, 23(1): 38-46. [Abstract] [Full-text]
  76. Mechanisms of the development of androgen independence in prostate cancer.
    World J Urol, 23(1): 1-9. [Abstract] [Full-text]
  77. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
    J Natl Cancer Inst, 97(6): 433-8. [Abstract] [Full-text]
  78. Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer.
    World J Urol, 23(1): 33-7. [Abstract] [Full-text]
  79. High molecular mass proteome of androgen-independent prostate cancer.
    Proteomics, 5(4): 1097-112. [Abstract] [Full-text]
  80. Decreased expression of e6-associated protein in breast and prostate carcinomas.
    Endocrinology, 146(4): 1707-12. [Abstract] [Full-text]
  81. Chemotherapy for androgen-independent prostate cancer.
    World J Urol, 23(1): 10-3. [Abstract] [Full-text]
  82. Rationale for the development and current status of calcitriol in androgen-independent prostate cancer.
    World J Urol, 23(1): 28-32. [Abstract] [Full-text]
  83. The role of bisphosphonates in hormone-refractory prostate cancer.
    World J Urol, 23(1): 14-8. [Abstract] [Full-text]
  84. Endothelin receptor antagonists.
    World J Urol, 23(1): 19-27. [Abstract] [Full-text]
  85. Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer.
    World J Urol, 23(1): 47-9. [Abstract] [Full-text]
  86. Bone turnover mediates preferential localization of prostate cancer in the skeleton.
    Endocrinology, 146(4): 1727-36. [Abstract] [Full-text]
  87. Characterization of linkage disequilibrium structure, mutation history, and tagging SNPs, and their use in association analyses: ELAC2 and familial early-onset prostate cancer.
    Genet Epidemiol, 28(3): 232-43. [Abstract] [Full-text]
  88. Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts.
    Mol Ther, 11(4): 542-52. [Abstract] [Full-text]
  89. Climacteric-like disorders in prostate cancer patients treated with LHRH agonists.
    Arch Androl, 51(1): 41-8. [Abstract] [Full-text]
  90. The 70 kilodalton heat shock protein is an inhibitor of apoptosis in prostate cancer.
    Int J Hyperthermia, 20(8): 835-49. [Abstract] [Full-text]
  91. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer.
    Urol Res, 33(1): 44-50. [Abstract] [Full-text]
  92. Putative role of serum insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3) levels in the development of prostate cancer in Arab men.
    Prostate Cancer Prostatic Dis, 8(1): 84-90. [Abstract] [Full-text]
  93. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy.
    J Clin Oncol, 23(9): 1962-8. [Abstract] [Full-text]
  94. Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes.
    J Clin Oncol, 23(9): 1911-20. [Abstract] [Full-text]
  95. CAG polymorphic repeat length in androgen receptor gene combined with pretreatment serum testosterone level as prognostic factor in patients with metastatic prostate cancer.
    Eur Urol, 47(4): 557-63. [Abstract] [Full-text]
  96. Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate.
    Eur Urol, 47(4): 449-54; discussion 454-5. [Abstract] [Full-text]
  97. High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer.
    Eur Urol, 47(4): 441-8. [Abstract] [Full-text]
  98. Effect of a nutritional supplement containing vitamin E, selenium, vitamin c and coenzyme Q10 on serum PSA in patients with hormonally untreated carcinoma of the prostate: a randomised placebo-controlled study.
    Eur Urol, 47(4): 433-9; discussion 439-40. [Abstract] [Full-text]
  99. Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer--a pilot study.
    Prostate Cancer Prostatic Dis, 8(1): 91-4. [Abstract] [Full-text]
  100. Association between hormonal genetic polymorphisms and early-onset prostate cancer.
    Prostate Cancer Prostatic Dis, 8(1): 95-102. [Abstract] [Full-text]
  101. The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer.
    Prostate Cancer Prostatic Dis, 8(1): 22-30. [Abstract] [Full-text]
  102. Does needle size matter? Patient experience of luteinising hormone-releasing hormone analogue injection.
    Prostate Cancer Prostatic Dis, 8(1): 66-8. [Abstract] [Full-text]
  103. Heterocyclic amines and genotype of N-acetyltransferases as risk factors for prostate cancer.
    Prostate Cancer Prostatic Dis, 8(1): 69-74. [Abstract] [Full-text]
  104. Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole.
    Prostate Cancer Prostatic Dis, 8(1): 75-83. [Abstract] [Full-text]
  105. Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease.
    Prostate Cancer Prostatic Dis, 8(1): 54-9. [Abstract] [Full-text]
  106. Risk of prostate cancer and family history of cancer: a population-based study in China.
    Prostate Cancer Prostatic Dis, 8(1): 60-5. [Abstract] [Full-text]
  107. Salvage cryosurgery for locally recurrent prostate cancer following radiotherapy.
    Prostate Cancer Prostatic Dis, 8(1): 31-5. [Abstract] [Full-text]
  108. TGFBR1*6A is not associated with prostate cancer in men of European ancestry.
    Prostate Cancer Prostatic Dis, 8(1): 50-3. [Abstract] [Full-text]
  109. Apoptotic regulators in prostatic intraepithelial neoplasia (PIN): value in prostate cancer detection and prevention.
    Prostate Cancer Prostatic Dis, 8(1): 7-13. [Abstract] [Full-text]
  110. MUC1 expression in human prostate cancer cell lines and primary tumors.
    Prostate Cancer Prostatic Dis, 8(1): 36-44. [Abstract] [Full-text]
  111. Proteome analysis of prostate cancer.
    Prostate Cancer Prostatic Dis, 8(1): 14-21. [Abstract] [Full-text]
  112. Mucin-producing urothelial-type adenocarcinoma of prostate: report of two cases of a rare and diagnostically challenging entity.
    Mod Pathol, 18(4): 585-90. [Abstract] [Full-text]
  113. Inhibition of tumor formation by snake venom disintegrin.
    Toxicon, 45(5): 661-9. [Abstract] [Full-text]
  114. Androgen receptor activation by G(s) signaling in prostate cancer cells.
    J Biol Chem, 280(12): 11583-9. [Abstract] [Full-text]
  115. Use of multiple biomarkers for a molecular diagnosis of prostate cancer.
    Int J Cancer, 114(6): 950-6. [Abstract] [Full-text]
  116. Gene expression profiling identifies IL-13 receptor alpha 2 chain as a therapeutic target in prostate tumor cells overexpressing adrenomedullin.
    Int J Cancer, 114(6): 870-8. [Abstract] [Full-text]
  117. Combined laser capture microdissection and serial analysis of gene expression from human tissue samples.
    Mod Pathol, 18(4): 577-84. [Abstract] [Full-text]
  118. Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer.
    Cancer Res, 65(6): 2498-504. [Abstract] [Full-text]
  119. Mimicry of a cellular low energy status blocks tumor cell anabolism and suppresses the malignant phenotype.
    Cancer Res, 65(6): 2441-8. [Abstract] [Full-text]
  120. Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells.
    Cancer Res, 65(6): 2378-86. [Abstract] [Full-text]
  121. The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome.
    Cancer Res, 65(6): 2330-6. [Abstract] [Full-text]
  122. Human osteocalcin and bone sialoprotein mediating osteomimicry of prostate cancer cells: role of cAMP-dependent protein kinase A signaling pathway.
    Cancer Res, 65(6): 2303-13. [Abstract] [Full-text]
  123. Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth.
    Cancer Res, 65(6): 2287-95. [Abstract] [Full-text]
  124. Immortalization of primary human prostate epithelial cells by c-Myc.
    Cancer Res, 65(6): 2179-85. [Abstract] [Full-text]
  125. Functional Loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancer.
    Cancer Res, 65(6): 2130-8. [Abstract] [Full-text]
  126. Activated Ras enhances insulin-like growth factor I induction of vascular endothelial growth factor in prostate epithelial cells.
    Cancer Res, 65(6): 2085-8. [Abstract] [Full-text]
  127. Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice.
    Cancer Res, 65(6): 2082-4. [Abstract] [Full-text]
  128. Ganoderma lucidum suppresses angiogenesis through the inhibition of secretion of VEGF and TGF-beta1 from prostate cancer cells.
    Biochem Biophys Res Commun, 330(1): 46-52. [Abstract] [Full-text]
  129. Chemoprevention of prostate cancer.
    Crit Rev Oncol Hematol, 54(1): 1-10. [Abstract] [Full-text]
  130. Prediction by quantitative histology of pathological stage in prostate cancer.
    Eur J Surg Oncol, 31(3): 309-13. [Abstract] [Full-text]
  131. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer.
    Ann Oncol, 16(4): 579-84. [Abstract] [Full-text]
  132. Hematopoietic cells regulate the angiogenic switch during tumorigenesis.
    Blood, 105(7): 2757-63. [Abstract] [Full-text]
  133. Mutation screening and association study of RNASEL as a prostate cancer susceptibility gene.
    Br J Cancer, 92(6): 1159-64. [Abstract] [Full-text]
  134. Involvement of transcription factor Sp1 in quercetin-mediated inhibitory effect on the androgen receptor in human prostate cancer cells.
    Carcinogenesis, 26(4): 793-801. [Abstract] [Full-text]
  135. Acacetin inhibits cell growth and cell cycle progression, and induces apoptosis in human prostate cancer cells: structure-activity relationship with linarin and linarin acetate.
    Carcinogenesis, 26(4): 845-54. [Abstract] [Full-text]
  136. Methylseleninic acid potentiates apoptosis induced by chemotherapeutic drugs in androgen-independent prostate cancer cells.
    Clin Cancer Res, 11(6): 2379-88. [Abstract] [Full-text]
  137. Reg IV: a promising marker of hormone refractory metastatic prostate cancer.
    Clin Cancer Res, 11(6): 2237-43. [Abstract] [Full-text]
  138. Expression profiling of androgen-dependent and -independent LNCaP cells: EGF versus androgen signalling.
    Endocr Relat Cancer, 12(1): 135-48. [Abstract] [Full-text]
  139. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
    Endocr Relat Cancer, 12(1): 119-34. [Abstract] [Full-text]
  140. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
    Endocr Relat Cancer, 12(1): 109-17. [Abstract] [Full-text]
  141. In situ androgen producing enzymes in human prostate cancer.
    Endocr Relat Cancer, 12(1): 101-7. [Abstract] [Full-text]
  142. Primary cell cultures as models of prostate cancer development.
    Endocr Relat Cancer, 12(1): 19-47. [Abstract] [Full-text]
  143. Estimated impact of the Prostate Cancer Prevention Trial on population mortality.
    Cancer, 103(7): 1375-80. [Abstract] [Full-text]
  144. Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer.
    Oncogene, 24(13): 2166-74. [Abstract] [Full-text]
  145. Estradiol and cognition during androgen deprivation in men with prostate carcinoma.
    Cancer, 103(7): 1381-7. [Abstract] [Full-text]
  146. Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions.
    Clin Chem, 51(4): 695-707. [Abstract] [Full-text]
  147. Simultaneous tumour-like, atypical basal cell hyperplasia and acinar adenocarcinoma of the prostate: a comparative morphological and genetic approach.
    Virchows Arch, 446(3): 338-41. [Abstract] [Full-text]
  148. Positron tomographic assessment of androgen receptors in prostatic carcinoma.
    Eur J Nucl Med Mol Imaging, 32(3): 344-50. [Abstract] [Full-text]
  149. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.
    FEBS Lett, 579(9): 1945-50. [Abstract] [Full-text]
  150. RM2 antigen (beta1,4-GalNAc-disialyl-Lc4) as a new marker for prostate cancer.
    Int J Cancer, 115(1): 105-13. [Abstract] [Full-text]
  151. Mass spectrometry-based expression profiling of clinical prostate cancer.
    Mol Cell Proteomics, 4(4): 545-54. [Abstract] [Full-text]
  152. Synergistic inhibitory effect of high-intensity focused ultrasound combined with chemotherapy on Dunning adenocarcinoma.
    BJU Int, 95(6): 881-5. [Abstract] [Full-text]
  153. The effect on erectile function of 103palladium implantation for localized prostate cancer.
    BJU Int, 95(6): 847-50. [Abstract] [Full-text]
  154. The assessment of patient life-expectancy: how accurate are urologists and oncologists?
    BJU Int, 95(6): 794-8. [Abstract] [Full-text]
  155. Sexual, psychological and dyadic qualities of the prostate cancer 'couple'.
    BJU Int, 95(6): 780-5. [Abstract] [Full-text]
  156. Testosterone recovery and changes in bone mineral density after stopping long-term luteinizing hormone-releasing hormone analogue therapy in osteoporotic patients with prostate cancer.
    BJU Int, 95(6): 776-9. [Abstract] [Full-text]
  157. The incidence and treatment of lymphoceles after radical retropubic prostatectomy.
    BJU Int, 95(6): 772-5. [Abstract] [Full-text]
  158. A novel technique for approaching the endopelvic fascia in retropubic radical prostatectomy, based on an anatomical study of fixed and fresh cadavers.
    BJU Int, 95(6): 766-71. [Abstract] [Full-text]
  159. Prostate-specific antigen (PSA) complexed to alpha1-antichymotrypsin improves prostate cancer detection using total PSA in Japanese patients with total PSA levels of 2.0-4.0 ng/mL.
    BJU Int, 95(6): 761-5. [Abstract] [Full-text]
  160. The influence of bladder neck mucosal eversion and early urinary extravasation on patient outcome after radical retropubic prostatectomy: a prospective controlled trial.
    BJU Int, 95(6): 757-60. [Abstract] [Full-text]
  161. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
    BJU Int, 95(6): 751-6. [Abstract] [Full-text]
  162. Effect of patient variation on standard- and hypo-fractionated radiotherapy of prostate cancer.
    Phys Med Biol, 50(7): 1483-92. [Abstract] [Full-text]
  163. Quantitation of the a priori dosimetric capabilities of spatial points in inverse planning and its significant implication in defining IMRT solution space.
    Phys Med Biol, 50(7): 1469-82. [Abstract] [Full-text]
  164. Dosimetric verification of IMRT treatment planning using Monte Carlo simulations for prostate cancer.
    Phys Med Biol, 50(5): 869-78. [Abstract] [Full-text]
  165. The progression of LNCaP human prostate cancer cells to androgen independence involves decreased FOXO3a expression and reduced p27KIP1 promoter transactivation.
    Mol Cancer Res, 3(3): 163-9. [Abstract] [Full-text]
  166. The value of contrast enhanced power Doppler ultrasonography in differentiating hypoehoic lesions in the peripheral zone of prostate.
    Eur J Radiol, 54(1): 148-55. [Abstract] [Full-text]
  167. Novel syngeneic pseudo-orthotopic prostate cancer model: vascular, mitotic and apoptotic responses to castration.
    Microvasc Res, 69(1): 1-9. [Abstract] [Full-text]
  168. Rectal complications after modern radiation for prostate cancer: a colorectal surgical challenge.
    J Gastrointest Surg, 9(4): 461-6. [Abstract] [Full-text]
  169. Serum levels of phytanic acid are associated with prostate cancer risk.
    Prostate, 63(3): 209-14. [Abstract] [Full-text]
  170. Description of the International Consortium For Prostate Cancer Genetics, and failure to replicate linkage of hereditary prostate cancer to 20q13.
    Prostate, 63(3): 276-90. [Abstract] [Full-text]
  171. Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation.
    Prostate, 63(3): 215-21. [Abstract] [Full-text]
  172. Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer.
    Prostate, 63(3): 231-9. [Abstract] [Full-text]
  173. 5alpha-dihydrotestosterone inhibits 1alpha,25-dihydroxyvitamin D3-induced expression of CYP24 in human prostate cancer cells.
    Prostate, 63(3): 222-30. [Abstract] [Full-text]
  174. Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer.
    Prostate, 63(3): 240-51. [Abstract] [Full-text]
  175. Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens.
    Prostate, 63(3): 252-8. [Abstract] [Full-text]
  176. Is quadrant biopsy sufficient in men likely to have advanced prostate cancer? Comparison with extended biopsy.
    Pathol Oncol Res, 11(1): 40-4. [Abstract] [Full-text]
  177. Prostate-specific antigen modulates the expression of genes involved in prostate tumor growth.
    Neoplasia, 7(3): 241-52. [Abstract] [Full-text]
  178. Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer.
    Neoplasia, 7(3): 207-23. [Abstract] [Full-text]
  179. Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer.
    Nat Genet, 37(4): 407-12. [Abstract] [Full-text]
  180. 3D proton MR spectroscopic imaging of prostate cancer using a standard spine coil at 1.5 T in clinical routine: a feasibility study.
    Eur Radiol, 15(4): 653-60. [Abstract] [Full-text]
  181. Three-dimensional 1H-magnetic resonance spectroscopy of the prostate in clinical practice: technique and results in patients with elevated prostate-specific antigen and negative or no previous prostate biopsies.
    Eur Radiol, 15(4): 645-52. [Abstract] [Full-text]
Place a permanent text-link or advertisement here.

© 2004-2013 Prostate Cancer Research Today. All Rights Reserved.



Prostate Cancer Research Today Archive:

Volume 1 (2004)
  Issue 1 (August)
  Issue 2 (September)
  Issue 3 (October)
  Issue 4 (November)
  Issue 5 (December)

Volume 2 (2005)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 3 (2006)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 4 (2007)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 5 (2008)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 6 (2009)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 7 (2010)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 8 (2011)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 9 (2012)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 10 (2013)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)



Prostate Cancer Books

PROSTATE CANCER MEETS THE PROTON BEAM: A Patient's Experience

PROSTATE CANCER MEETS THE PROTON BEAM: A Patient's Experience